$CLRB

Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 2026 results and corporate updates. It initiated site activation for a Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA planned for mid-2027 under FDA Accelerated Approval. ASCO data showed 79.2% MRR (n=24) post-BTKi. CLR 125 Phase 1b TNBC enrollment began. Cash was $34.0M at June 30, 2026.

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623056d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned

Cellectar Biosciences (NASDAQ: CLRB) said a Phase 1 open-label study of iopofosine I 131 plus low-dose dexamethasone in 31 relapsed or refractory multiple myeloma patients was published in Cancers. Among 26 efficacy-evaluable patients, 84.6% had stable disease or better, with a 30% overall response rate in those receiving at least 60 mCi. Safety was manageable, mainly reversible cytopenias.

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2620219d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CELLECTAR BIOSCIENCES, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED SECTION 1. General Purpose of the Plan; Definitions The purpose of this 2021 Stock Incentive Plan (the “Plan”) is to encourage and enable officers and empl

Cellectar Biosciences has appointed Andrew Gu as a Class III director and Audit Committee member to its board, effective May 18, 2026. Concurrently, Stefan D. Loren has chosen not to seek reelection but will transition to a consulting role for one year starting July 8, 2026, where he will be compensated quarterly and granted stock options. Gu, an analyst at Nantahala focusing on biotech investments, was selected by Nantahala for the board position.

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Chief Operating Officer Jarrod Longcor recently increased his holdings by purchasing 8,680 shares of common stock at $2.88 per share and 26,040 warrants at $0.01 per warrant. These open-market transactions, which occurred on May 7, 2026, increased his direct ownership to 20,451 common shares and 36,149 warrants. The warrants are exercisable for common stock at $2.88, with varying expiration terms of one, two, and five years from stockholder approval.

Cellectar Biosciences has enrolled the first patient in its Phase 1b clinical trial of CLR 125, an Auger-emitting radioconjugate, for refractory triple-negative breast cancer (TNBC). This trial will evaluate the safety, tolerability, and preliminary efficacy of CLR 125 at three different dose levels and regimens. The company aims to address the significant unmet medical need for targeted therapies in this aggressive form of breast cancer.

Cellectar Biosciences, Inc. announced it will release its full year 2025 financial results and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. The company will host a conference call and webcast to discuss these results. Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform.

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory ( post-BTKi ) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party ...